1. Executive Summary |
2. Global Multiple Sclerosis Market Introduction |
2.1. Global Multiple Sclerosis Market – Taxonomy |
2.2. Global Multiple Sclerosis Market –Definitions |
2.2.1. Disease Type |
2.2.2. Treatment |
2.2.3. Drug Class |
2.2.4. Diagnosis |
2.2.5. Route of Administration |
2.2.6. Region |
3. Global Multiple Sclerosis Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Global Multiple Sclerosis Market Dynamic Factors - Impact Analysis |
3.6. Global Multiple Sclerosis Market – Competition Landscape |
4. Global Multiple Sclerosis Market Analysis,2017 - 2021 - and Forecast, 2022 2028 |
4.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5. Global Multiple Sclerosis Market, By Disease Type, 2017–2021 and Forecast, 2022–2028 (Revenue, USD Mn) |
5.1. Clinically Isolated Syndrome (CIS) |
5.1.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Relapsing-Remitting MS (RRMS) |
5.2.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. Secondary Progressive MS (SPMS) |
5.3.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
5.4. Primary Progressive MS (PPMS) |
5.4.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.4.3. Market Opportunity Analysis |
6. Global Multiple Sclerosis Market, By Treatment, 2017 – 2021 and Forecast, 2021 – 2027 (Revenue, USD Mn) |
6.1. Medications |
6.1.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Physical Therapy |
6.2.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Plasma Exchange |
6.3.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
6.4. Stem Cell Therapy |
6.4.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.4.3. Market Opportunity Analysis |
7. Global Multiple Sclerosis Market Forecast, By Drug Class, 2017–2021and Forecast, 2022–2028 (Revenue, USD Mn) |
7.1. Corticosteroids |
7.1.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Immunomodulators |
7.2.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Sphingosine l-phosphate receptor modulators |
7.3.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
7.4. Nrf2 activators |
7.4.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.4.3. Market Opportunity Analysis |
7.5. Purine analogs |
7.5.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.5.3. Market Opportunity Analysis |
7.6. Humanized Monoclonal Antibody |
7.6.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
7.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.6.3. Market Opportunity Analysis |
7.7. Muscle relaxants |
7.7.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
7.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.7.3. Market Opportunity Analysis |
7.8. Adamantanes |
7.8.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
7.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.8.3. Market Opportunity Analysis |
7.9. Potassium Channel Blockers |
7.9.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
7.9.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.9.3. Market Opportunity Analysis |
7.10. Immunosuppressants |
7.10.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
7.10.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.10.3. Market Opportunity Analysis |
7.11. Interferons |
7.11.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
7.11.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.11.3. Market Opportunity Analysis |
7.12. Others |
7.12.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
7.12.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.12.3. Market Opportunity Analysis |
8. Global Multiple Sclerosis Market Forecast, By Diagnosis, 2017 – 2021 and Forecast, 2021 – 2027 (Revenue, USD Mn) |
8.1. Magnetic Resonance Imaging |
8.1.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Simple Electrical Stimulation Tests |
8.2.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Lumbar Puncture |
8.3.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
9. Global Multiple Sclerosis Market, By Route of Administration, 2017 – 2021 and Forecast, 2021 – 2027 (Revenue, USD Mn) |
9.1. Oral |
9.1.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.1.3. Market Opportunity Analysis |
9.2. Parenteral |
9.2.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.2.3. Market Opportunity Analysis |
9.3. Others |
9.3.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.3.3. Market Opportunity Analysis |
10. Global Multiple Sclerosis Market Forecast, By Region, 2017–2021and Forecast, 2022–2028(Revenue, USD Mn) |
10.1. North America |
10.1.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
10.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
10.1.3. Market Opportunity Analysis |
10.2. Europe |
10.2.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
10.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
10.2.3. Market Opportunity Analysis |
10.3. Asia-Pacific |
10.3.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
10.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
10.3.3. Market Opportunity Analysis |
10.4. Latin America |
10.4.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
10.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
10.4.3. Market Opportunity Analysis |
10.5. Middle East and Africa |
10.5.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
10.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
10.5.3. Market Opportunity Analysis |
10.6. Global Multiple Sclerosis Market - Opportunity Analysis Index, By Treatment, Drug Class, Disease Type, Diagnosis, Route of Administration and Region, 2022 - 2028 |
11. North America Multiple Sclerosis MarketAnalysis,2017–2021and Forecast, 2022–2028(Revenue, USD Mn) |
11.1. Disease Type Analysis 2017–2021and Forecast 2022 - 2028by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%) |
11.1.1. Clinically Isolated Syndrome (CIS) |
11.1.2. Relapsing-Remitting MS (RRMS) |
11.1.3. Secondary Progressive MS (SPMS) |
11.1.4. Primary Progressive MS (PPMS) |
11.2. Treatment Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
11.2.1. Medications |
11.2.2. Physical Therapy |
11.2.3. Plasma Exchange |
11.2.4. Stem Cell Therapy |
11.3. Drug Class Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
11.3.1. Corticosteroids |
11.3.2. Immnumomodulators |
11.3.3. Sphingosine l-phosphate receptor modulators |
11.3.4. Nrf2 activators |
11.3.5. Purine analogs |
11.3.6. Humanized Monoclonal Antibody |
11.3.7. Muscle relaxants |
11.3.8. Adamantanes |
11.3.9. Potassium Channel Blockers |
11.3.10. Immunosuppresents |
11.3.11. Interferons |
11.3.12. Others |
11.4. Diagnosis Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
11.4.1. Magnetic Resonance Imaging |
11.4.2. Simple Electrical Stimulation Tests |
11.4.3. Lumbar Puncture |
11.4.4. others |
11.5. Route of Administration Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
11.5.1. Oral |
11.5.2. Parenteral |
11.5.3. Others |
11.6. Country Analysis 2017 - 2021 and Forecast 2022 - 2028by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
11.6.1. USA |
11.6.2. Canada |
11.7. North America Multiple Sclerosis Market - Opportunity Analysis Index, By Treatment, Drug Class, Disease Type, Diagnosis, Route of Administration and Country, 2022 - 2028 |
11.8. North America Multiple Sclerosis Market Dynamics – Trends |
12. Europe Multiple Sclerosis Market Analysis, 2017–2021and Forecast, 2022–2028(Revenue, USD Mn) |
12.1. Disease Type Analysis 2017–2021and Forecast 2022 - 2028by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%) |
12.1.1. Clinically Isolated Syndrome (CIS) |
12.1.2. Relapsing-Remitting MS (RRMS) |
12.1.3. Secondary Progressive MS (SPMS) |
12.1.4. Primary Progressive MS (PPMS) |
12.2. Treatment Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
12.2.1. Medications |
12.2.2. Physical Therapy |
12.2.3. Plasma Exchange |
12.2.4. Stem Cell Therapy |
12.3. Drug Class Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
12.3.1. Corticosteroids |
12.3.2. Immnumomodulators |
12.3.3. Sphingosine l-phosphate receptor modulators |
12.3.4. Nrf2 activators |
12.3.5. Purine analogs |
12.3.6. Humanized Monoclonal Antibody |
12.3.7. Muscle relaxants |
12.3.8. Adamantanes |
12.3.9. Potassium Channel Blockers |
12.3.10. Immunosuppresents |
12.3.11. Interferons |
12.3.12. Others |
12.4. Diagnosis Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
12.4.1. Magnetic Resonance Imaging |
12.4.2. Simple Electrical Stimulation Tests |
12.4.3. Lumbar Puncture |
12.4.4. others |
12.5. Route of Administration Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
12.5.1. Oral |
12.5.2. Parenteral |
12.5.3. Others |
12.6. Country Analysis 2017–2021and Forecast 2022 - 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
12.6.1. Germany |
12.6.2. UK |
12.6.3. France |
12.6.4. Spain |
12.6.5. Italy |
12.6.6. Russia |
12.6.7. Poland |
12.6.8. Rest of Europe |
12.7. Europe Multiple Sclerosis Market - Opportunity Analysis Index, By Treatment, Drug Class, Disease Type, Diagnosis, Route of Administrationand Country, 2022 - 2028 |
12.8. Europe Multiple Sclerosis Market Dynamics – Trends |
13. Asia-Pacific Multiple Sclerosis Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
13.1. Disease Type Analysis 2017–2021and Forecast 2022 - 2028by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%) |
13.1.1. Clinically Isolated Syndrome (CIS) |
13.1.2. Relapsing-Remitting MS (RRMS) |
13.1.3. Secondary Progressive MS (SPMS) |
13.1.4. Primary Progressive MS (PPMS) |
13.2. Treatment Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
13.2.1. Medications |
13.2.2. Physical Therapy |
13.2.3. Plasma Exchange |
13.2.4. Stem Cell Therapy |
13.3. Drug Class Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
13.3.1. Corticosteroids |
13.3.2. Immnumomodulators |
13.3.3. Sphingosine l-phosphate receptor modulators |
13.3.4. Nrf2 activators |
13.3.5. Purine analogs |
13.3.6. Humanized Monoclonal Antibody |
13.3.7. Muscle relaxants |
13.3.8. Adamantanes |
13.3.9. Potassium Channel Blockers |
13.3.10. Immunosuppresents |
13.3.11. Interferons |
13.3.12. Others |
13.4. Diagnosis Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
13.4.1. Magnetic Resonance Imaging |
13.4.2. Simple Electrical Stimulation Tests |
13.4.3. Lumbar Puncture |
13.4.4. others |
13.5. Route of Administration Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
13.5.1. Oral |
13.5.2. Parenteral |
13.5.3. Others |
13.6. Country Analysis2017–2021and Forecast 2022 - 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
13.6.1. Japan |
13.6.2. China |
13.6.3. India |
13.6.4. ASEAN |
13.6.5. Australia & New Zealand |
13.6.6. Rest of Asia-Pacific |
13.7. Asia-Pacific Multiple Sclerosis Market - Opportunity Analysis Index, By Treatment, Drug Class, Disease Type, Diagnosis, Route of Administration and Country,2022 - 2028 |
13.8. Asia-Pacific Multiple Sclerosis Market Dynamics – Trends |
14. Latin America Multiple Sclerosis Market Analysis,2017 - 2021 and Forecast, 2022–2028(Revenue, USD Mn) |
14.1. Disease Type Analysis 2017–2021and Forecast 2022 - 2028by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%) |
14.1.1. Clinically Isolated Syndrome (CIS) |
14.1.2. Relapsing-Remitting MS (RRMS) |
14.1.3. Secondary Progressive MS (SPMS) |
14.1.4. Primary Progressive MS (PPMS) |
14.2. Treatment Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
14.2.1. Medications |
14.2.2. Physical Therapy |
14.2.3. Plasma Exchange |
14.2.4. Stem Cell Therapy |
14.3. Drug Class Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
14.3.1. Corticosteroids |
14.3.2. Immnumomodulators |
14.3.3. Sphingosine l-phosphate receptor modulators |
14.3.4. Nrf2 activators |
14.3.5. Purine analogs |
14.3.6. Humanized Monoclonal Antibody |
14.3.7. Muscle relaxants |
14.3.8. Adamantanes |
14.3.9. Potassium Channel Blockers |
14.3.10. Immunosuppresents |
14.3.11. Interferons |
14.3.12. Others |
14.4. Diagnosis Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
14.4.1. Magnetic Resonance Imaging |
14.4.2. Simple Electrical Stimulation Tests |
14.4.3. Lumbar Puncture |
14.4.4. others |
14.5. Route of Administration Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
14.5.1. Oral |
14.5.2. Parenteral |
14.5.3. Others |
14.6. Country Analysis 2017–2021and Forecast 2022 - 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
14.6.1. Brazil |
14.6.2. Mexico |
14.6.3. Argentina |
14.6.4. Rest of Latin America |
14.7. Latin America Multiple Sclerosis Market - Opportunity Analysis Index, By Treatment, Drug Class, Disease Type, Diagnosis, Route of Administration and Country, 2022 - 2028 |
14.8. Latin America Multiple Sclerosis Market Dynamics – Trends |
15. Middle East and Africa Multiple Sclerosis Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
15.1. Disease Type Analysis 2017–2021and Forecast 2022 - 2028by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%) |
15.1.1. Clinically Isolated Syndrome (CIS) |
15.1.2. Relapsing-Remitting MS (RRMS) |
15.1.3. Secondary Progressive MS (SPMS) |
15.1.4. Primary Progressive MS (PPMS) |
15.2. Treatment Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
15.2.1. Medications |
15.2.2. Physical Therapy |
15.2.3. Plasma Exchange |
15.2.4. Stem Cell Therapy |
15.3. Drug Class Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
15.3.1. Corticosteroids |
15.3.2. Immnumomodulators |
15.3.3. Sphingosine l-phosphate receptor modulators |
15.3.4. Nrf2 activators |
15.3.5. Purine analogs |
15.3.6. Humanized Monoclonal Antibody |
15.3.7. Muscle relaxants |
15.3.8. Adamantanes |
15.3.9. Potassium Channel Blockers |
15.3.10. Immunosuppresents |
15.3.11. Interferons |
15.3.12. Others |
15.4. Diagnosis Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
15.4.1. Magnetic Resonance Imaging |
15.4.2. Simple Electrical Stimulation Tests |
15.4.3. Lumbar Puncture |
15.4.4. others |
15.5. Route of Administration Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
15.5.1. Oral |
15.5.2. Parenteral |
15.5.3. Others |
15.6. Country Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
15.6.1. Gulf Cooperation Council (GCC) Countries |
15.6.2. Israel |
15.6.3. South Africa |
15.6.4. Rest of MEA |
15.7. MEA Multiple Sclerosis Market - Opportunity Analysis Index, By Treatment, Drug Class, Disease Type, Diagnosis, Route of Administration and Country, 2022 - 2028 |
15.8. MEA Multiple Sclerosis Market Dynamics – Trends |
16. Competition Landscape |
16.1. Strategic Dashboard of Top Market Players |
16.2. Company Profiles (Introduction, Financial Analysis, Treatment& Service Drug Class, Key Developments, Strategies, and SWOT Analysis) |
16.2.1. F. Hoffmann-La Roche Ltd. |
16.2.2. Mylan N.V. |
16.2.3. Teva Pharmaceutical Industries Ltd. |
16.2.4. Sanofi |
16.2.5. Pfizer Inc. |
16.2.6. GlaxoSmithKline plc |
16.2.7. Novartis AG |
16.2.8. Bayer AG |
16.2.9. Eli Lilly and Company |
16.2.10. Merck & Co., Inc. |
16.2.11. Allergan |
16.2.12. AstraZeneca |
16.2.13. Johnson & Johnson Private Limited |
16.2.14. Cipla Inc. |
16.2.15. Abbott |
16.2.16. AbbVie Inc. |
16.2.17. Merck KGaA |
16.2.18. Actelion Pharmaceuticals Ltd |
16.2.19. Opexa Therapeutics, Inc. |
16.2.20. Bayer AG |
17. Research Methodology |
18. Key Assumptions and Acronyms |
2021 is the base year and 2028 is the forecast year.
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.